news
Connected drug delivery devices market to grow to $4bn by 2028
A new report reveals the COVID-19 pandemic, prevalence of chronic disease and increasing patient engagement will all drive adoption of connected drug delivery devices.
List view / Grid view
Merck KGaA
webinar
Roadmap to compliance in environmental monitoring
5 October 2020 | By Merck KGaA
This on-demand webinar provides an overview of a holistic approach to achieve compliance with good manufacturing practice (GMP) requirements for environmental monitoring (EM) in aseptic manufacturing areas, such as ISO 5 cleanrooms in traditional setup, RABS or isolators.
news
Germany to lead aseptic sampling market in Europe
A new report has revealed that Germany is set to lead the aseptic sampling market in Europe, contributing $35.7 million to the market until 2025.
news
Metastatic NSCLC therapy, tepotinib, given Breakthrough Designation
Tepotinib, an investigational therapy for patients with metastatic non-small cell lung cancer has been given Breakthrough Therapy Designation.
article
Culturing diversity to empower success
As part of EPR’s Women in Pharma series, Elisabeth Prchla, Managing Director at Merck KGaA, talks to Science Editor Dr Zara Kassam about the secrets of overcoming gender imbalance and harnessing science and innovation...
news
Infoholics reports growth for polymerase chain reaction market
The global polymerase chain reaction market is estimated to witness a compound annual growth rate CAGR of 9.91% during the forecast period 2017–2023...
news
Bioreactors and Fermenters market to reach US $4461 million by 2024
The global Bioreactors and Fermenters Market features a largely consolidated vendor landscape and a low to moderate level of competition, says a new report...
article
Fertile ground: Why Merck is investing in fertility treatment centres
1 March 2017 | By Dorothea Wenzel, Senior VP Global Business Franchise Fertility, Merck
We caught up with Merck's Dorothea Wenzel to hear all about the latest in fertility treatments, training and technologies and to find out the truth about infertility...
news
Phase III trial to evaluate avelumab as first-line treatment in ovarian cancer
6 July 2016 | By Victoria White, Digital Content Producer
Avelumab will be evaluated in combination with, and/or as follow-on treatment to, platinum-based chemotherapy in patients with epithelial ovarian cancer...
news
Immunotherapy shrinks tumours in neuroblastoma patients
3 June 2016 | By Victoria White, Digital Content Producer
Neuroblastoma tumours shrank in 80% of young, high-risk patients enrolled in a Phase II clinical trial that included an experimental monoclonal antibody...
news
Trial to investigate avelumab and entinostat in ovarian cancer
4 January 2016 | By Victoria White
Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody and entinostat is an investigational oral small molecule that targets immune regulatory cells...
news
Merck KGaA and Pfizer advance avelumab clinical development programme
22 December 2015 | By
Merck KGaA and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients with ovarian cancer...
news
Evofosfamide fails in two late-stage cancer trials
7 December 2015 | By Victoria White
Merck KGaA will also not be pursuing the treatment in pancreatic adenocarcinoma after the drug failed in two late-stage clinical trials...
news
COMP issues positive opinion for ODD for avelumab in MCC
1 December 2015 | By Victoria White
An official decision on the Ophran Drug Designation is expected from the European Commission in December...
news
FDA grants Breakthrough Therapy designation to avelumab for MCC
18 November 2015 | By Victoria White
Avelumab (MSB0010718C) is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody...
